Rather than rest in success, Dr. Chang took a keen interest in Ansun Biopharma, a company founded in 2003 by virologists and molecular biologists pursuing a novel approach to treat otherwise untreatable viral flu strains. Ansun’s founding intentions were true, its science was solid, and in those early days, its funding was secure. In fact, from 2004 through 2011 the company received a number of research grants in addition to a $50 million contract from the NIH to develop the experimental anti-influenza agent Fludase.